Increased expression of galectin-1,-3,-8, and -9 has been confirmed in human MS lesions (Stancic et al., 2011), and the concentration of anti-galectin-1 autoantibodies is increased in the serum of MS patients (Lutomski et al., 1997). This evidence concerns the gene LGALS1 and myeloid sarcoma.